Taysha Gene Therapies (TSHA) Enterprise Value (2022 - 2025)
Taysha Gene Therapies (TSHA) has disclosed Enterprise Value for 4 consecutive years, with -$320.2 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 130.79% to -$320.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$320.2 million through Dec 2025, down 130.79% year-over-year, with the annual reading at -$320.2 million for FY2025, 130.79% down from the prior year.
- Enterprise Value hit -$320.2 million in Q4 2025 for Taysha Gene Therapies, down from -$297.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$36.9 million in Q3 2022 to a low of -$320.2 million in Q4 2025.
- Historically, Enterprise Value has averaged -$147.0 million across 4 years, with a median of -$131.6 million in 2024.
- Biggest YoY gain for Enterprise Value was 36.11% in 2023; the steepest drop was 344.68% in 2023.
- Year by year, Enterprise Value stood at -$87.9 million in 2022, then crashed by 62.55% to -$142.8 million in 2023, then rose by 2.87% to -$138.7 million in 2024, then crashed by 130.79% to -$320.2 million in 2025.
- Business Quant data shows Enterprise Value for TSHA at -$320.2 million in Q4 2025, -$297.8 million in Q3 2025, and -$313.2 million in Q2 2025.